Nuveen Asset Management LLC Sells 74,087 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Nuveen Asset Management LLC decreased its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 32.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 153,077 shares of the company's stock after selling 74,087 shares during the quarter. Nuveen Asset Management LLC owned about 0.29% of Zevra Therapeutics worth $1,277,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. increased its position in shares of Zevra Therapeutics by 462.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock worth $30,441,000 after purchasing an additional 3,001,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Zevra Therapeutics by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock worth $23,554,000 after purchasing an additional 68,151 shares during the last quarter. Altium Capital Management LLC increased its position in shares of Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after purchasing an additional 150,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after purchasing an additional 144,256 shares during the last quarter. Finally, AIGH Capital Management LLC acquired a new position in shares of Zevra Therapeutics during the 4th quarter worth approximately $6,577,000. Institutional investors and hedge funds own 35.03% of the company's stock.

Analyst Ratings Changes

ZVRA has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Canaccord Genuity Group boosted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Finally, Guggenheim boosted their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $22.29.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA traded up $0.43 on Friday, reaching $9.26. The stock had a trading volume of 1,339,820 shares, compared to its average volume of 659,190. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a fifty day moving average of $7.76 and a two-hundred day moving average of $8.07. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76. The company has a market cap of $506.34 million, a P/E ratio of -4.70 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same period in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director John B. Bode bought 10,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.40% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.